Foundational Science and Mechanisms of Disease

426 questions

Question 421Question →

A 54-year-old woman comes to the clinic due to persistent joint pain and morning stiffness. She was diagnosed with rheumatoid arthritis two years ago and has been taking oral methotrexate, but her symptoms remain poorly controlled. Physical examination shows active synovitis and effusion in the bilateral metacarpophalangeal and proximal interphalangeal joints. The physician plans to initiate a tumor necrosis factor (TNF) alpha inhibitor. Before starting the new medication, an interferon-gamma release assay is obtained and is positive. A chest radiograph shows no abnormalities, and she has no cough, night sweats, or weight loss. The physician decides to delay the biologic therapy and initiates a course of rifampin. The proposed biologic therapy increases the risk of disease reactivation in this patient by directly impairing which of the following immunologic processes?

Show answer & explanation

Answer: Maintenance of macrophage-rich organized cellular aggregates

Answer

Maintenance of macrophage-rich organized cellular aggregates
The correct answer identifies the maintenance of macrophage-rich organized cellular aggregates (granulomas). The patient's positive IGRA and asymptomatic presentation indicate latent tuberculosis infection (LTBI). In LTBI, Mycobacterium tuberculosis is contained within caseating granulomas in the lungs. Tumor necrosis factor-alpha (TNF-alpha), secreted primarily by macrophages and T cells, is a critical cytokine that sustains macrophage activation and maintains the architectural integrity of these granulomas. The use of a TNF-alpha inhibitor disrupts this delicate balance, leading to the dissolution of the granuloma and subsequent reactivation and dissemination of the mycobacteria. Consequently, patients must be screened for and treated for LTBI prior to starting TNF-alpha inhibitor therapy.

Step-by-Step Solution

1
Interpret the pre-treatment screening results.
The patient has a positive interferon-gamma release assay (IGRA) with a normal chest radiograph and no systemic symptoms, confirming a diagnosis of latent tuberculosis infection (LTBI).
Screening for latent tuberculosis is mandatory before initiating biologic therapies that suppress cell-mediated immunity.
2
Identify the pharmacologic target of the proposed therapy.
The planned medication is a TNF-alpha inhibitor.
Understanding the drug class allows correlation with its specific immunologic effects.
3
Correlate the mechanism of the drug with the underlying pathology of the infection.
TNF-alpha is essential for activating macrophages and maintaining the structural integrity of caseating granulomas. Inhibiting TNF-alpha will cause granuloma breakdown, leading to the reactivation of latent tuberculosis.
This explains the physiological basis for the absolute contraindication of starting TNF-alpha inhibitors prior to treating LTBI.

Key Concept

Tumor necrosis factor-alpha (TNF-alpha) is vital for the maintenance of granulomas in latent tuberculosis; administration of TNF-alpha inhibitors disrupts this immunologic process, predisposing patients to life-threatening reactivation of the disease.
Question 422Question →

A 6464-year-old woman is evaluated in the oncology clinic to discuss systemic therapy for newly diagnosed metastatic colorectal cancer. Two weeks ago, she underwent a right hemicolectomy for an obstructing cecal mass. Intraoperative findings and subsequent imaging confirmed the presence of unresectable bilobar hepatic metastases. Pathology of the primary tumor demonstrated moderately differentiated adenocarcinoma. Comprehensive molecular profiling of the tumor tissue reveals a missense mutation in codon 1212 of the KRAS gene. The patient has no other significant past medical history and her Eastern Cooperative Oncology Group (ECOG) performance status is 00. The medical team plans to initiate a combination cytotoxic chemotherapy regimen. Based on the molecular pathology findings, the addition of a monoclonal antibody directed against which of the following targets is specifically contraindicated due to lack of therapeutic benefit?

Show answer & explanation

Answer: Epidermal growth factor receptor

Answer

Epidermal growth factor receptor
Epidermal growth factor receptor (EGFR) signaling is a critical driver of cellular proliferation in colorectal carcinoma. The KRAS gene encodes a small GTPase protein that functions directly downstream of EGFR in the RAS-RAF-MEK-ERK signaling cascade. When a patient has a KRAS mutation (most commonly in codons 12, 13, or 61), the resulting RAS protein remains locked in a constitutively active, GTP-bound state. This leads to continuous downstream signaling and tumor growth regardless of upstream receptor activation. Because the pathway is continuously activated downstream of the receptor, administering monoclonal antibodies that block the upstream Epidermal growth factor receptor (such as cetuximab or panitumumab) provides no therapeutic benefit. Consequently, anti-EGFR therapies are specifically contraindicated in patients with KRAS-mutated colorectal cancer.

Step-by-Step Solution

1
Analyze the patient's diagnosis and molecular profiling results.
The patient has metastatic colorectal cancer with a KRAS codon 12 mutation.
Identifying actionable molecular targets is required to predict therapeutic response and avoid ineffective treatments.
2
Determine the role of the KRAS mutation in tumor intracellular signaling.
Mutated KRAS protein remains in a constitutively active state, causing continuous activation of the downstream RAS-RAF-MEK-ERK pathway regardless of upstream receptor activity.
Understanding the precise location of the mutated protein within the cellular signaling cascade is necessary to anticipate mechanisms of pharmacologic resistance.
3
Identify the targeted therapy class that is contraindicated by this mechanism.
Monoclonal antibodies directed against the Epidermal growth factor receptor (EGFR) are contraindicated because blocking the upstream receptor fails to halt the downstream constitutive signaling driven by the KRAS mutation.
Evidence-based guidelines mandate KRAS testing before initiating anti-EGFR therapies to prevent the administration of ineffective and potentially toxic agents.

Key Concept

Patients with metastatic colorectal cancer harboring KRAS mutations are inherently resistant to anti-EGFR monoclonal antibodies (e.g., cetuximab, panitumumab) because the mutated RAS protein continuously drives cellular proliferation downstream, independent of upstream EGFR blockade.
Question 423Question →

A 42-year-old man presents to the outpatient clinic with a 2-year history of worsening joint pain, excessive sweating, and an increase in his shoe size. On physical examination, he has a prominent brow, macroglossia, and enlarged, doughy hands. Visual field testing is normal. Laboratory evaluation reveals a markedly elevated serum insulin-like growth factor-1 (IGF-1) concentration. Following administration of a 75-gram oral glucose load, serum growth hormone (GH) levels remain elevated. The hormone directly responsible for the peripheral somatic changes observed in this patient exerts its cellular effects via which of the following intracellular signaling mechanisms?

Show answer & explanation

Answer: Autophosphorylation of intrinsic receptor tyrosine kinase residues

Answer

The correct answer is autophosphorylation of intrinsic receptor tyrosine kinase residues.
This patient presents with classic signs of acromegaly, a condition typically caused by a growth hormone (GH)-secreting anterior pituitary adenoma. The excess GH stimulates the liver to synthesize and release insulin-like growth factor-1 (IGF-1). While GH has direct metabolic actions (e.g., insulin resistance, lipolysis), IGF-1 is the hormone directly responsible for the peripheral somatic manifestations of acromegaly, such as skeletal overgrowth, macroglossia, and soft tissue enlargement. The IGF-1 receptor is a receptor tyrosine kinase that is structurally highly homologous to the insulin receptor. When IGF-1 binds to its cell membrane receptor, it induces a conformational change that leads to the autophosphorylation of intrinsic intracellular tyrosine residues. This initiates a complex intracellular signaling cascade, primarily involving the PI3K/AKT and MAPK pathways, which promotes cellular growth, proliferation, and survival.

Step-by-Step Solution

1
Diagnose the clinical condition.
The clinical presentation (somatic overgrowth, macroglossia) and lab findings (elevated IGF-1, failure of GH to suppress with glucose) are classic for acromegaly.
Establishing the diagnosis identifies the primary pathophysiological axis (GH/IGF-1 axis).
2
Identify the specific hormone asked about in the question.
The question asks for the signaling mechanism of the hormone directly responsible for the peripheral somatic changes, which is insulin-like growth factor-1 (IGF-1), not growth hormone (GH).
While GH is secreted by the pituitary adenoma, it acts primarily on the liver to stimulate the production of IGF-1. IGF-1 mediates the vast majority of the peripheral tissue growth seen in acromegaly.
3
Determine the intracellular signaling pathway of the identified hormone.
IGF-1 binds to the IGF-1 receptor, which is a receptor tyrosine kinase structurally homologous to the insulin receptor. Ligand binding induces autophosphorylation of intrinsic tyrosine residues.
Knowing specific hormone receptor classes is essential for foundational science applications in endocrinology.

Key Concept

Insulin-like growth factor-1 (IGF-1) mediates the peripheral somatic changes of acromegaly by binding to a receptor tyrosine kinase, leading to intrinsic autophosphorylation.
Question 424Question →

An endocrinology consult team is evaluating laboratory panels for four different patients who have presented with perturbations in calcium and phosphate homeostasis. To establish the correct diagnosis and formulate a management plan, the underlying pathophysiology must be identified. Match each patient's specific biochemical profile with the precise cellular or metabolic mechanism responsible for the findings.

Click a left item, then click its matching right item

Items

Elevated serum calcium, decreased serum phosphate, elevated intact PTH
Decreased serum calcium, elevated serum phosphate, elevated intact PTH, low 1,25-dihydroxyvitamin D
Elevated serum calcium, high-normal serum phosphate, suppressed intact PTH, elevated 1,25-dihydroxyvitamin D
Elevated serum calcium, decreased serum phosphate, suppressed intact PTH, elevated PTHrP

Matches

Show answer & explanation

Answer

Profile 1 maps to autonomous chief cell hypersecretion (primary hyperparathyroidism). Profile 2 maps to loss of renal parenchyma and 1-alpha-hydroxylase activity (CKD). Profile 3 maps to extra-renal macrophage conversion of vitamin D (granulomatous disease). Profile 4 maps to tumor secretion of a PTH analog (humoral hypercalcemia of malignancy).
Each laboratory profile distinctly reflects a specific disruption in the calcium-PTH-vitamin D axis. High calcium with inappropriately high PTH points to primary parathyroid autonomy. Low calcium with high phosphate points to renal failure (secondary hyperparathyroidism). High calcium with suppressed PTH and high active vitamin D points to ectopic 1-alpha-hydroxylase activity (granulomas). High calcium with suppressed PTH and high PTHrP points to a paraneoplastic syndrome.

Step-by-Step Solution

1
Analyze the PTH level in the context of serum calcium.
Elevated calcium with elevated PTH indicates a parathyroid-dependent mechanism (Profile 1). Elevated calcium with suppressed PTH indicates a parathyroid-independent mechanism (Profiles 3 and 4).
Intact PTH should normally be suppressed by hypercalcemia via the calcium-sensing receptor. Failure of suppression indicates autonomous PTH secretion.
2
Evaluate the suppressed PTH profiles using vitamin D and PTHrP data.
Profile 4 has elevated PTHrP, confirming ectopic secretion by a tumor. Profile 3 has elevated 1,25-dihydroxyvitamin D despite suppressed PTH, pointing to an unregulated extra-renal source.
Differentiating parathyroid-independent hypercalcemia requires localizing the source of calcium mobilization (exogenous vitamin D, ectopic PTHrP, or local osteolysis).
3
Assess the hypocalcemic profile.
Profile 2 shows low calcium, high phosphate, and low active vitamin D despite high PTH.
This triad perfectly reflects chronic kidney disease, where the organ responsible for phosphate excretion and final vitamin D activation is failing, leading to secondary hyperparathyroidism.

Key Concept

Differential diagnosis of calcium and phosphate homeostasis disorders based on PTH, vitamin D, and PTHrP pathways
Question 425Question →

A 38-year-old man is evaluated in the nephrology clinic for a gradual increase in serum creatinine over the past two weeks. He underwent a deceased-donor renal transplantation 8 months ago for end-stage renal disease secondary to IgA nephropathy. His current medications include tacrolimus, mycophenolate mofetil, and prednisone. His blood pressure is 148/92 mmHg. Physical examination is unremarkable, and the patient reports no fever or dysuria. Laboratory studies show a serum creatinine of 2.6 mg/dL, an increase from his baseline of 1.3 mg/dL. A renal ultrasound reveals normal allograft size with no hydronephrosis and normal resistive indices. A renal allograft biopsy is performed. Immunofluorescence staining of the biopsy specimen reveals diffuse, strong linear deposition of C4d along the peritubular capillaries. Which of the following is the most likely initiating immunopathologic event responsible for this patient's current allograft dysfunction?

Show answer & explanation

Answer: Binding of newly formed recipient immunoglobulins to donor human leukocyte antigens

Answer

The correct answer is the binding of newly formed recipient immunoglobulins to donor human leukocyte antigens.
The correct answer identifies the fundamental pathophysiology of acute antibody-mediated rejection (AMR). AMR is caused by the development of *de novo* donor-specific antibodies (DSAs) in the recipient, which bind to donor human leukocyte antigens (HLAs) on the graft endothelium. This antigen-antibody complex powerfully activates the classical complement cascade, leading to the cleavage of C4 and the covalent binding of the inactive C4d fragment to the local endothelial surface. Therefore, diffuse peritubular capillary C4d staining is considered the hallmark diagnostic signature of AMR.

Step-by-Step Solution

1
Analyze the clinical presentation and timeline.
The patient is 8 months post-renal transplant and presents with acute allograft dysfunction (elevated creatinine).
Establishing the timeline helps rule out hyperacute rejection (minutes to hours) and makes acute or chronic processes more likely.
2
Interpret the specific diagnostic biopsy finding.
The biopsy shows diffuse linear deposition of C4d along peritubular capillaries.
C4d is a degradation product of the classical complement pathway. Its presence on the endothelium is a specific marker for antibody-antigen interaction in the transplanted organ.
3
Correlate the biopsy finding with the immunopathologic mechanism.
C4d positivity indicates Acute Antibody-Mediated Rejection (AMR), which is caused by the recipient forming donor-specific antibodies (DSAs) against the donor's HLA molecules.
Identifying the correct mechanism is required to select the targeted option differentiating it from T-cell-mediated cellular rejection or drug toxicity.

Key Concept

Acute Antibody-Mediated Rejection (AMR) pathophysiology
Question 426Question →

An emergency department physician evaluates a 34-year-old woman presenting with a 3-day history of continuous epistaxis, heavy menstrual bleeding, and diffuse ecchymoses. She reports profound fatigue over the past week but denies fever or weight loss. Her temperature is 37.1°C (98.8°F), blood pressure is 110/70 mmHg, and pulse is 105/min. Physical examination reveals widespread petechiae over her lower extremities.

Laboratory studies reveal the following:

ParameterResultReference Range
Hemoglobin8.2 g/dL12.0-15.5 g/dL
Platelet count28,000/mm³150,000-400,000/mm³
Leukocyte count18,000/mm³4,500-11,000/mm³
Prothrombin time (PT)18 seconds11-15 seconds
Activated partial thromboplastin time (aPTT)45 seconds25-40 seconds
Fibrinogen95 mg/dL200-400 mg/dL

A peripheral blood smear demonstrates numerous mononuclear cells with intensely granulated cytoplasm and prominent needle-like cytoplasmic inclusions.

Which of the following is the most appropriate initial step in the management of this patient's condition?

Show answer & explanation

Answer: Administer all-trans retinoic acid

Answer

Administer all-trans retinoic acid
The patient's presentation of bleeding, DIC (low fibrinogen, elevated PT/aPTT, thrombocytopenia), and a peripheral smear showing promyelocytes with Auer rods is pathognomonic for Acute Promyelocytic Leukemia (APL). The molecular driver of APL is the t(15;17) translocation, creating the PML-RARA fusion protein that halts myeloid differentiation. The primary cause of early mortality in APL is severe hemorrhage secondary to DIC, which is triggered by tissue factor released from the neoplastic promyelocytes. The most critical initial management step is the immediate administration of all-trans retinoic acid (ATRA). ATRA binds the mutated receptor, overriding the differentiation block and allowing the cells to mature, which rapidly halts the release of procoagulants and stabilizes the coagulopathy.

Step-by-Step Solution

1
Interpret the clinical and laboratory presentation.
The patient has pancytopenia with a consumptive coagulopathy characterized by prolonged PT/aPTT, thrombocytopenia, and hypofibrinogenemia, indicative of disseminated intravascular coagulation (DIC).
Recognizing DIC is crucial for identifying the immediate life-threatening risk of catastrophic hemorrhage.
2
Correlate the hematologic derangements with the peripheral smear findings.
The presence of heavily granulated mononuclear cells containing needle-like inclusions (Auer rods) in the setting of severe DIC is highly specific for Acute Promyelocytic Leukemia (APL).
APL promyelocytes contain primary granules loaded with tissue factor and annexin II, which trigger the coagulation cascade and cause DIC.
3
Determine the most appropriate immediate medical intervention.
All-trans retinoic acid (ATRA) must be administered immediately upon suspicion of APL, even before genetic confirmation of the t(15;17) translocation.
ATRA overcomes the retinoic acid receptor alpha (RARA) mutation, inducing the malignant promyelocytes to differentiate into mature neutrophils. This stops the release of procoagulant factors and resolves the life-threatening DIC.

Key Concept

Immediate administration of all-trans retinoic acid (ATRA) is the critical first step in suspected Acute Promyelocytic Leukemia (APL) to resolve life-threatening disseminated intravascular coagulation (DIC).
PreviousPage 22 / 22
Foundational Science and Mechanisms of Disease Practice Questions — USMLE Step 3 — Page 22 | Examkin